An immuno polymerase chain reaction screen for the detection of CJC-1295 and other growth-hormone-releasing hormone analogs in equine plasma

The development of sensitive detection methods for therapeutic peptides advances both analytical science and our understanding of peptide pharmacology. This study by Timms, Ganio, Forbes, and colleagues developed a highly sensitive immuno polymerase chain reaction screen for detecting CJC-1295 and other GHRH analogs in equine plasma.

The researchers combined immunoassay specificity with PCR amplification to create an ultra-sensitive detection method capable of identifying CJC-1295 at very low concentrations in biological samples. This innovative analytical approach pushed the boundaries of peptide detection sensitivity.

The development of such a highly sensitive detection method underscores CJC-1295's significant biological potency, as even trace amounts of the peptide produce measurable biological effects. The sustained growth hormone-releasing activity of CJC-1295 is reflected in its persistent presence in biological fluids, confirming its long-acting pharmacological profile.

For the clinical application of CJC-1295, this analytical advance supports better understanding of the peptide's pharmacokinetics and duration of action. The ability to detect and measure CJC-1295 at very low levels contributes to dosing optimization and quality assurance in growth hormone secretagogue therapy protocols.